Shares of Kadmon Holdings Inc (NYSE:KDMN) saw strong trading volume on Friday . 1,184,371 shares traded hands during mid-day trading, an increase of 6% from the previous session’s volume of 1,119,463 shares.The stock last traded at $4.48 and had previously closed at $4.48.
Several research analysts have commented on the stock. Piper Jaffray Companies reissued a “positive” rating and issued a $9.00 price target (up from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Kadmon in a report on Friday, March 9th. Zacks Investment Research downgraded shares of Kadmon from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Jefferies Group raised their price target on shares of Kadmon to $16.00 and gave the company a “buy” rating in a report on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $10.21.
The firm has a market capitalization of $337.38, a price-to-earnings ratio of -3.01 and a beta of 5.59.
Kadmon (NYSE:KDMN) last posted its quarterly earnings data on Tuesday, March 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $3.07 million. During the same period in the prior year, the firm posted ($0.50) earnings per share. The business’s revenue was down 65.1% on a year-over-year basis. sell-side analysts expect that Kadmon Holdings Inc will post -1.1 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares during the period. Vanguard Group Inc. raised its position in Kadmon by 166.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after purchasing an additional 941,549 shares during the period. Goldman Sachs Group Inc. purchased a new position in Kadmon in the 2nd quarter worth $114,000. Bank of New York Mellon Corp purchased a new position in Kadmon in the 3rd quarter worth $119,000. Finally, AE Wealth Management LLC raised its position in Kadmon by 33.6% in the 3rd quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock worth $1,083,000 after purchasing an additional 81,226 shares during the period. 61.71% of the stock is owned by institutional investors.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.